# Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas

> **NCT04122911** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute, Naples** · enrollment: 25 (actual)

## Conditions studied

- Neuroendocrine Carcinomas

## Interventions

- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT04122911
- **Lead sponsor:** National Cancer Institute, Naples
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-29
- **Primary completion:** 2017-12-30
- **Final completion:** 2019-12-16
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2020-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04122911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04122911, "Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04122911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*